The Impact of Opioids on Epigenetic Modulation in Myocardial Ischemia and Reperfusion Injury: Focus on Non-coding RNAs.

IF 2.4 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Translational Research Pub Date : 2025-04-08 DOI:10.1007/s12265-025-10609-y

Mohsen Davari, Mahmoud Khansari, Sahar Hosseini, Reza Morovatshoar, Alireza Azani, Seyedeh Tarlan Mirzohreh, Mohammadjavad Ashrafi Mahabadi, Moein Ghasemi, Mohammad Saeed Soleimani Meigoli, Sima Foroughi Nematollahi, Sina Pourranjbar, Qumars Behfar, Mandana Baghdadi, Ahmad Mir Hosseini

{"title":"The Impact of Opioids on Epigenetic Modulation in Myocardial Ischemia and Reperfusion Injury: Focus on Non-coding RNAs.","authors":"Mohsen Davari, Mahmoud Khansari, Sahar Hosseini, Reza Morovatshoar, Alireza Azani, Seyedeh Tarlan Mirzohreh, Mohammadjavad Ashrafi Mahabadi, Moein Ghasemi, Mohammad Saeed Soleimani Meigoli, Sima Foroughi Nematollahi, Sina Pourranjbar, Qumars Behfar, Mandana Baghdadi, Ahmad Mir Hosseini","doi":"10.1007/s12265-025-10609-y","DOIUrl":null,"url":null,"abstract":"<p><p>Myocardial ischemia-reperfusion injury (IRI) is a major issue in cardiovascular medicine, marked by tissue damage from the restoration of blood flow after ischemia. Opioids, known for their pain-relieving properties, have emerged as potential cardioprotective agents in IRI. Recent research suggests opioids influence epigenetic mechanisms-such as histone modifications and non-coding RNAs (ncRNAs)-which are essential for regulating gene expression and cellular responses during myocardial IRI. This review delves into how opioids like remifentanil affect histone modifications, DNA methylation, and ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Remifentanil postconditioning (RPC) reduces apoptosis in cardiomyocytes through histone deacetylation, specifically downregulating histone deacetylase 3 (HDAC3). Similarly, opioids impact miRNAs such as miR- 206 - 3p and miR- 320 - 3p, and lncRNAs like TINCR and UCA1, which influence apoptosis, inflammation, and oxidative stress. Understanding these interactions highlights the potential for opioid-based therapies in mitigating IRI-induced myocardial damage.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Translational Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12265-025-10609-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Myocardial ischemia-reperfusion injury (IRI) is a major issue in cardiovascular medicine, marked by tissue damage from the restoration of blood flow after ischemia. Opioids, known for their pain-relieving properties, have emerged as potential cardioprotective agents in IRI. Recent research suggests opioids influence epigenetic mechanisms-such as histone modifications and non-coding RNAs (ncRNAs)-which are essential for regulating gene expression and cellular responses during myocardial IRI. This review delves into how opioids like remifentanil affect histone modifications, DNA methylation, and ncRNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Remifentanil postconditioning (RPC) reduces apoptosis in cardiomyocytes through histone deacetylation, specifically downregulating histone deacetylase 3 (HDAC3). Similarly, opioids impact miRNAs such as miR- 206 - 3p and miR- 320 - 3p, and lncRNAs like TINCR and UCA1, which influence apoptosis, inflammation, and oxidative stress. Understanding these interactions highlights the potential for opioid-based therapies in mitigating IRI-induced myocardial damage.

查看原文本刊更多论文

阿片类药物对心肌缺血再灌注损伤表观遗传调控的影响：以非编码rna为重点。

心肌缺血再灌注损伤（IRI）是心血管医学中的一个主要问题，其特征是缺血后血流恢复导致组织损伤。阿片类药物以其镇痛特性而闻名，已成为IRI中潜在的心脏保护剂。最近的研究表明，阿片类药物影响表观遗传机制，如组蛋白修饰和非编码rna (ncRNAs)，这对于调节心肌IRI期间的基因表达和细胞反应至关重要。这篇综述深入研究了像瑞芬太尼这样的阿片类药物如何影响组蛋白修饰、DNA甲基化和ncRNAs，包括microRNAs （miRNAs）和长链非编码rna （lncRNAs）。瑞芬太尼后处理（Remifentanil postconditioning， RPC）通过组蛋白去乙酰化，特别是下调组蛋白去乙酰化酶3 (HDAC3)，减少心肌细胞凋亡。同样，阿片类药物影响miR- 206 - 3p和miR- 320 - 3p等mirna，以及TINCR和UCA1等lncrna，影响细胞凋亡、炎症和氧化应激。了解这些相互作用强调了阿片类药物治疗在减轻iri诱导的心肌损伤方面的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cardiovascular Translational Research CARDIAC & CARDIOVASCULAR SYSTEMS-MEDICINE, RESEARCH & EXPERIMENTAL

CiteScore

6.10

自引率

2.90%

发文量

148

审稿时长

6-12 weeks

期刊介绍： Journal of Cardiovascular Translational Research (JCTR) is a premier journal in cardiovascular translational research. JCTR is the journal of choice for authors seeking the broadest audience for emerging technologies, therapies and diagnostics, pre-clinical research, and first-in-man clinical trials. JCTR''s intent is to provide a forum for critical evaluation of the novel cardiovascular science, to showcase important and clinically relevant aspects of the new research, as well as to discuss the impediments that may need to be overcome during the translation to patient care.